seekingalpha.com

Scholar Rock Discusses Apitegromab Ahead of FDA PDUFA Date at Biopharma Summit

Scholar Rock Holding logoScholar Rock Holding
Sig1.82Sen+3.65Env0.00Soc+1.55Gov+0.60

Scholar Rock highlights 15 years since its founding and says it is about three weeks from an FDA PDUFA date for apitegromab, a monoclonal antibody myostatin inhibitor. The company describes Phase III results in 188 patients with spinal muscular atrophy, citing statistically meaningful motor function improvement on the Hammersmith Motor Function Scale and frames the approach for muscular atrophies and dystrophies.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro